Company Profile

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE612.951.9 (+0.31 % )
PREV CLOSE (Rs.) 611.05
OPEN PRICE (Rs.) 613.00
BID PRICE (QTY) 612.95 (148 )
OFFER PRICE (QTY) 613.50 (191 )
VOLUME 19918
TODAY'S LOW / HIGH (Rs.)610.85 616.20
52 WK LOW / HIGH (Rs.)543.8 718.35
NSE611.90 1.65 (+0.27 % )
PREV CLOSE(Rs.) 610.25
OPEN PRICE (Rs.) 614.90
BID PRICE (QTY) 611.90 (12 )
OFFER PRICE (QTY) 612.00 (39 )
VOLUME 394887
TODAY'S LOW / HIGH(Rs.) 610.40 615.90
52 WK LOW / HIGH (Rs.)543.3 718

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.16
TTM EPS (Rs.) 8.24
P/E Ratio 74.34
Book Value (Rs.) 118.33
Face Value (Rs.) 5
MCap (Rs. in Mn) 367290.00
Price/Earning (TTM) 57.75
Price/Sales (TTM) 13.26
Price/Book (MRQ) 5.17
PAT Margin (%) 9.83
ROCE (%) 4.53
Incorporation Year : 1978

Management Info :

Kiran Mazumdar-Shaw - Chairman Kiran Mazumdar-Shaw - Managing Director

Registered Office :

Address : 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone : 91-80-2808-2808

Website : www.biocon.com

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
19Mar03-19-2019$Biocon informs about investor meet Biocon informs about investo

Biocon has informed about meeting conducted with Institutional Investors/Research Analysts under Regulation 30 (6) of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Biocon has informed about meeting conducted with Institutional..
16Mar03-16-2019$Biocon informs about resignation of CS cum CO Biocon informs about resigna

Biocon has informed that Satish Kumar SS, Company Secretary and Compliance Officer of the Company has resigned from his position, effective from closing business hours of March 15, 2019. Consequent to the resignation, Siddharth Mittal, President Finance and Chief Financial Officer will act as interim Compliance Officer of the Company in place of Satish Kumar SS, and authorised to make necessary communications and filings with the stock exchanges or any other regulatory authority(ies), till the appointment of new Company Secretary and Compliance Officer.

The above information is a part of company’s filings submitted to BSE.

Biocon has informed that Satish Kumar SS, Company Secretary and..
07Mar03-07-2019$USFDA concludes inspection of Biocon's insulin drug substance manufacturing facility USFDA concludes inspection o

US Food and Drug Administration (USFDA) has concluded a pre-approval inspection of Biocon's insulin drug substance manufacturing facility triggered by a New Drug Application (NDA).

The inspection at the Bengaluru facility took place on February 25 - March 05, 2019, resulting in a Form 483 with six observations.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

US Food and Drug Administration (USFDA) has concluded a pre-app..
18Feb02-18-2019$USFDA concludes two pre approval inspections of Biocon's facilities in Bengaluru USFDA concludes two pre appr

The US Food and Drug Administration (USFDA) has concluded two pre approval inspections of Biocon's manufacturing facilities in Bengaluru. There were no observations and no form 483 was issued after the pre-approval inspection of Biocon's Oral Solid Dosage Facility conducted between February 11-15, 2019.

The pre-approval inspection of the company's additional, new injectable manufacturing line for a biologic drug product, conducted between February 7-15, 2019, resulted in a form 483 with two observations. Biocon intends to address these expeditiously.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

The US Food and Drug Administration (USFDA) has concluded two p..
18Feb02-18-2019$Biocon informs about disclosure Biocon informs about disclos

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, Biocon has informed that the company complete Pre Approval US FDA Inspection.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, B..
Financials More
Rs. in Millions
QTR Dec 18 ANNUAL 18
Net Profit7272385
Gross Profit 820 3058
Operating Profit 12054429
Net Sales 739724255
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Piramal Enterprises (BSE)
 2615.50 (1.61%)
M.Cap ( in Cr)
48047.83
Valiant Organics (BSE)
 1575.00 (1.94%)
M.Cap ( in Cr)
923.64
Sanofi India (BSE)
 5590.00 (0.53%)
M.Cap ( in Cr)
12875.61
Torrent Pharma (BSE)
 1881.00 (0.94%)
M.Cap ( in Cr)
31929.69
Alkem Laboratories (BSE)
 1723.75 (0.56%)
M.Cap ( in Cr)
20601.05
Shareholding Pattern More
PROMOTERS 60.67 %
MUTUAL FUNDS/UTI 2.96 %
NON-INSTITUTION 17.26 %
FI/BANKS/INSURANCE 1.16 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested